Advicenne S.A.

Paris Stock Exchange ALDVI.PA

Advicenne S.A. EBIT Margin for the year ending December 31, 2023: -205.08%

Advicenne S.A. EBIT Margin is -205.08% for the year ending December 31, 2023, a 52.22% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Advicenne S.A. EBIT Margin for the year ending December 31, 2022 was -429.24%, a 7.44% change year over year.
  • Advicenne S.A. EBIT Margin for the year ending December 31, 2021 was -463.74%, a 33.59% change year over year.
  • Advicenne S.A. EBIT Margin for the year ending December 31, 2020 was -698.30%, a 2.00% change year over year.
  • Advicenne S.A. EBIT Margin for the year ending December 31, 2019 was -712.55%, a -66.88% change year over year.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
SV Wall Street
Paris Stock Exchange: ALDVI.PA

Advicenne S.A.

CEO Mr. Didier Laurens
IPO Date Dec. 6, 2017
Location France
Headquarters 3ème étage 262
Employees 21
Sector Healthcare
Industries
Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Fertilizers Glass
Description

Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.

StockViz Staff

February 6, 2025

Any question? Send us an email